
Aptinyx APTX
Quarterly report 2023-Q1
added 05-18-2023
Aptinyx Accounts Payables 2011-2026 | APTX
Accounts payable — are the obligations of an organization to other legal entities or individuals that arise in cases when the company has acquired goods or services on deferred payment terms, has not paid taxes and fees, has wage arrears to employees, or has received loans and other liabilities. Accounts payable arise when an organization has already received some benefit but has not yet paid for it.Main types of accounts payable
| Type of liability | Example |
|---|---|
| To suppliers and contractors | Goods received but not yet paid for |
| Taxes and fees | VAT, income tax, etc., not paid on time |
| Salaries | Employee wages not paid |
| To budgets | Insurance contributions to funds not paid |
| To founders | Founders provided borrowed funds |
| To banks | Overdue loan payments |
| Other | Fines, penalties, forfeits, customer prepayments, etc. |
Impact on the company's financial performance
- Liquidity and solvency
Accounts payable are part of short-term liabilities, so they affect liquidity ratios - Financial stability
The higher the share of borrowed funds (including accounts payable), the lower the company's level of independence - Capital turnover
Moderate accounts payable can positively affect working capital by allowing the company to use “free” financing from suppliers (payment deferrals) - Risks and reputation
Large and especially overdue accounts payable may indicate financial difficulties. This can deter investors, partners, and lenders, and at a critical level of debt and lack of resources to repay it, bankruptcy proceedings may be initiated
Annual Accounts Payables Aptinyx
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 724 K | 622 K | 1.21 M | 1.56 M | 1.89 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.89 M | 622 K | 1.2 M |
Quarterly Accounts Payables Aptinyx
| 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.37 M | 724 K | 474 K | - | 1.75 M | 622 K | 3.12 M | 434 K | 1.67 M | 1.21 M | 1.21 M | 1.21 M | 1.21 M | 1.56 M | 1.56 M | 1.56 M | 1.56 M | 1.89 M | 1.89 M | 1.89 M | 1.89 M | 1.54 M | 1.54 M | 1.54 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 3.12 M | 434 K | 1.45 M |
Accounts Payables of other stocks in the Biotechnology industry
| Issuer | Accounts Payables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Alector
ALEC
|
1.69 M | $ 2.08 | -14.4 % | $ 214 M | ||
|
Acer Therapeutics
ACER
|
3.81 M | - | 2.71 % | $ 14 M | ||
|
Altimmune
ALT
|
211 K | $ 4.2 | -2.67 % | $ 298 M | ||
|
Apellis Pharmaceuticals
APLS
|
56.8 M | $ 20.24 | -3.44 % | $ 2.55 B | ||
|
Aptorum Group Limited
APM
|
3.24 M | $ 0.8 | 1.87 % | $ 4.36 M | ||
|
Aprea Therapeutics
APRE
|
1.67 M | $ 0.88 | -3.72 % | $ 3.18 M | ||
|
I-Mab
IMAB
|
570 M | - | - | $ 866 M | ||
|
Aquestive Therapeutics
AQST
|
10.3 M | $ 4.1 | 2.37 % | $ 356 M | ||
|
AgeX Therapeutics
AGE
|
1.41 M | - | -10.17 % | $ 12.2 K | ||
|
Arcturus Therapeutics Holdings
ARCT
|
7.19 M | $ 8.35 | 1.46 % | $ 225 M | ||
|
Ardelyx
ARDX
|
19.2 M | $ 6.37 | -2.75 % | $ 1.54 B | ||
|
Aeglea BioTherapeutics
AGLE
|
677 K | - | - | $ 1.01 B | ||
|
Armata Pharmaceuticals
ARMP
|
1.58 M | $ 10.91 | 1.58 % | $ 394 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
2.91 M | - | - | $ 26.5 M | ||
|
Arcutis Biotherapeutics
ARQT
|
12.5 M | $ 25.33 | -6.1 % | $ 3.22 B | ||
|
Arvinas
ARVN
|
24.4 M | $ 12.97 | -2.3 % | $ 920 M | ||
|
Arrowhead Pharmaceuticals
ARWR
|
17.7 M | $ 61.74 | -2.42 % | $ 8.26 B | ||
|
Actinium Pharmaceuticals
ATNM
|
897 K | $ 1.17 | -0.85 % | $ 35.2 M | ||
|
Atossa Therapeutics
ATOS
|
806 K | $ 4.39 | -0.9 % | $ 553 M | ||
|
Atara Biotherapeutics
ATRA
|
4.37 M | $ 5.01 | -7.47 % | $ 37.5 M | ||
|
Aurinia Pharmaceuticals
AUPH
|
3.31 M | $ 14.14 | -0.21 % | $ 1.9 B | ||
|
ARCA biopharma
ABIO
|
3.46 M | - | 1052.0 % | $ 415 M | ||
|
Acorda Therapeutics
ACOR
|
13.4 M | - | -24.86 % | $ 820 K | ||
|
Autolus Therapeutics plc
AUTL
|
1.97 M | $ 1.68 | -1.75 % | $ 429 M | ||
|
Acasti Pharma
ACST
|
601 K | - | 4.01 % | $ 150 M | ||
|
Atea Pharmaceuticals
AVIR
|
4.46 M | $ 4.69 | 0.21 % | $ 395 M | ||
|
Adverum Biotechnologies
ADVM
|
1.61 M | - | - | $ 86.2 M | ||
|
Anavex Life Sciences Corp.
AVXL
|
4.25 M | $ 4.54 | 2.44 % | $ 387 M | ||
|
Akero Therapeutics
AKRO
|
9.03 M | - | - | $ 3.67 B | ||
|
Akouos
AKUS
|
1.28 M | - | 0.23 % | $ 488 M | ||
|
Albireo Pharma
ALBO
|
6.52 M | - | -0.23 % | $ 916 M | ||
|
Axon Enterprise
AXON
|
72 M | $ 570.5 | 5.18 % | $ 43.2 B | ||
|
Axsome Therapeutics
AXSM
|
65.5 M | $ 162.28 | -0.98 % | $ 8.07 B | ||
|
Allena Pharmaceuticals
ALNA
|
1.03 M | - | 3.16 % | $ 1.9 M | ||
|
Aytu BioScience
AYTU
|
10.6 M | $ 2.56 | -0.58 % | $ 16.1 M | ||
|
Aileron Therapeutics
ALRN
|
911 K | - | 10.36 % | $ 9.8 M | ||
|
AlloVir
ALVR
|
247 K | - | 4.14 % | $ 49.1 M | ||
|
Alpine Immune Sciences
ALPN
|
4.29 M | - | - | $ 2.17 B |